Clinical trials: Cardiac Disease
Ventricular Tachycardia (VT), Atrial Tachycardia
Clinical Study on the Efficiency of Rapid Arrhythmia Mapping Using EasyStars™ High Density Mapping Catheter Applications
The primary objective of this study was to evaluate the clinical feasibility, safety, and surgical characteristics of the EasyStars™ High Density Mapping Catheterin in patients with complex arrhythmias.
- Conditions
- Ventricular Tachycardia (VT), Atrial Tachycardia, Typical Atrial Flutter, Paroxysmal Atrial Fibrillation (PAF)
- Trial name
- Rapid Arrhythm (NCT07079813)
- Testing
- EasyStars™ High Density Mapping Catheter
- Volunteers
- 300 people
- Sponsor
- Shanghai MicroPort EP MedTech Co., Ltd.
Cardiac Arrhythmia
Non-invasive Tool to Assess Electrophysiological Mechanisms in Cardiac Arrhythmias
Noninvasive evaluation of the electrical status of the heart is based on the standard ECG but remains suboptimal due to difficulties with arrhythmia characterization and location.
- Trial name
- SAVE-COR (NCT05772182)
- Testing
- ACORYS MAPPING SYSTEM
- Where
- 3 sites in Spain
- Volunteers
- 362 people
- Sponsor
- Corify Care S.L.
Atrial Fibrillation, Embolic Stroke of Undetermined Source
An Open-label Study of EZYPRO® in Atrial Fibrillation Detection on ESUS Patients
The aim of the study is to evaluate the effectiveness and safety of the 14-day continuous ECG patch monitor (EZYPRO®) compared with a 24-hour Holter monitor in the detection of atrial fibrillation (AF) among ESUS patients.
- Trial name
- NCT05089435
- Testing
- EZYPRO® ECG Recorder
- Where
- Taiwan
- Volunteers
- 500 people
- Sponsor
- Sigknow Biomedical Co., Ltd.
Heart Failure, Congestive, Sleep Apnea Syndromes
Investigation of Heart Failure Status Over Time Using Respiratory Parameters
The purpose of the study is to investigate respiratory indicators for clinically important changes in Heart Failure status over time.
- Trial name
- NCT00494117
- Testing
- ApneaLink
- Where
- Australia
- Volunteers
- 50 people
- Sponsor
- ResMed
Coronary Occlusion
Safety and Efficacy of the CiTop™ Guidewire for Crossing Chronic Total Occlusions in Coronary Arteries
The CiTop™ guidewire Coronary study is a feasibility open label study, to evaluate the safety and efficacy of the CiTop™ Guidewire for crossing chronic total occlusion in Coronary arteries.
- Trial name
- NCT00618020
- Testing
- CiTop(tm) Guidewire
- Where
- India
- Volunteers
- 10 people
- Sponsor
- Ovalum
Mitral Valve Regurgitation (Degenerative or Functional)
TVMR With the INNOVALVE System Trial - Early Feasibility Study
Study to evaluate the safety and performance of the INNOVALVE system
- Trial name
- TWIST-EFS (NCT04919980)
- Testing
- INNOVALVE system
- Where
- 21 sites in United States
- Volunteers
- 85 people
- Sponsor
- Edwards Lifesciences
Ischemic Heart Disease
A Phase 1 Study to Assess the Safety,Tolerability, and Pharmacokinetics of GS-6615 in Healthy Subjects
This is a phase 1, single-blind, randomized, placebo-controlled, multiple ascending dose study aimed to assess the safety, tolerability, and pharmacokinetics of GS-6615 in healthy subjects.
- Trial name
- NCT01847391
- Testing
- GS-6615
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Mitral Valve Insufficiency
The Half Moon Transcatheter Mitral Valve Repair (TMVr) Pilot Study
The study is a prospective, multi-center, single-arm, non-randomized, Early Feasibility Study (EFS) to evaluate the safety and performance of the Half Moon TMVr System in patients with severe, symptomatic mitral regurgitation…
- Trial name
- NCT04343313
- Testing
- Half Moon TMVr System
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Half Moon Medical
Acute Coronary Syndromes
CER-001 Atherosclerosis Regression ACS Trial
The purpose of this study is to assess the impact of ten intravenous infusions of 3 mg/kg CER 001 vs. placebo, given at weekly intervals for ten weeks, on atherosclerotic plaque volume as measured by coronary IVUS, when…
- Trial name
- CARAT (NCT02484378)
- Testing
- CER-001
- Where
- 35 sites in United States, Australia and 2 more
- Volunteers
- 301 people
- Sponsor
- Cerenis Therapeutics, SA
Acquired Bleeding Disorder, Cardiac Surgery Requiring Cardiopulmonary Bypass
Activated Recombinant Human Factor VII Following Cardiac Bypass Surgery for Paediatric Congenital Heart Disease
This trial is conducted in Oceania. The aim of this trial is to investigate the efficacy of activated recombinant human factor VII and standard treatment compared with standard haemostatic replacement therapy in cardiopulmonary…
- Trial name
- NCT01562574
- Testing
- activated recombinant human factor VII
- Where
- Australia
- Volunteers
- 82 people
- Sponsor
- Novo Nordisk A/S
Atrial Fibrillation, Atrial Flutter
Double Blind Placebo COntrolled Dose Ranging studY of the eFficacy and safEty of SSR149744c 300 or 600 mg for the Conversion of Atrial Fibrillation / fluttEr
Double blind study to assess versus placebo the efficacy of SSR149744C for the conversion of atrial fibrillation/flutter to sinus rhythm at the time of the planned electrical cardioversion.
- Trial name
- CORYFEE (NCT00232310)
- Testing
- CELIVARONE (SSR149744C)
- Where
- 9 sites in United States, Canada and 7 more
- Volunteers
- 150 people
- Sponsor
- Sanofi
Atrial Fibrillation
Tracking Results of Ablations to Combat AF Registry Generation 2
The primary objective of the TRAC-AF Registry is to capture real-world safety and effectiveness data on AtriCure devices used to conduct open concomitant and/or hybrid ablation, and management of the LAA concomitant to a cardiac…
- Trial name
- TRAC-AF (NCT05111015)
- Testing
- Open Concomitant Surgical Ablation Procedures, Hybrid (Convergent) Ablation Procedures, AtriCure Hybrid Totally Thoracoscopic Ablation Procedures
- Where
- 29 sites in United States, Austria and 1 more
- Volunteers
- 10,000 people
- Sponsor
- AtriCure, Inc.
Paroxysmal Atrial Fibrillation
Ablation of the Pulmonary Veins for Paroxysmal Afib
The purpose of this trial was to investigate and confirm the safety, efficacy, and efficiency of the Ablation Frontiers® Cardiac Ablation System when used in the treatment of paroxysmal atrial fibrillation. (PAF)
- Trial name
- MAP-PAF (NCT00744874)
- Testing
- RF Ablation procedure
- Where
- 5 sites in Denmark, Germany and 2 more
- Volunteers
- 55 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Ventricular Tachycardia, Ventricular Fibrillation
DF4 Connector System Post-Approval Study
The purpose of this study is to evaluate long-term performance of the DF4 Connector System. This evaluation is based on the number of DF4 lead-related complications occurring during the study compared to the number of leads…
- Conditions
- Ventricular Tachycardia, Ventricular Fibrillation, Sudden Cardiac Death, Heart Failure
- Trial name
- NCT01638897
- Where
- 78 sites in United States, Canada and 1 more
- Volunteers
- 1,778 people
- Sponsor
- Medtronic
Paroxysmal Atrial Fibrillation
DIAMOND AF Post-Approval Study
The DIAMOND AF Post Approval study is a prospective, global, multi-center, non-randomized, single-arm observational trial
- Trial name
- DAF PAS (NCT05230524)
- Testing
- DiamondTemp™ Ablation System
- Where
- 5 sites in United States, France and 1 more
- Volunteers
- 84 people
- Sponsor
- Medtronic Cardiac Ablation Solutions
Coronary Artery Disease
Open Label Study to Access Flurpiridaz F18 in PET MPI Verses SPECT MPI
The study will evaluate the use of Flurpiridaz F18 injection in patients with CAD to determine if the study drug in PET imaging is better than SPECT imaging currently used for this purpose.
- Trial name
- NCT01681524
- Testing
- Flurpiridaz F18
- Sponsor
- Lantheus Medical Imaging
Heart Failure
Benefits of Microcor in Ambulatory Decompensated Heart Failure
To assess investigator engagement of μCor system data in the context of heart failure management. The μCor system includes a sensor and wearable patch for fluid management.
- Trial name
- BMAD-TX (NCT04096040)
- Testing
- μCor
- Where
- 83 sites in United States, Austria and 2 more
- Volunteers
- 265 people
- Sponsor
- Zoll Medical Corporation
Heart Failure
Efficacy of Candesartan on Symptomatic Heart Failure in Treating Diabetic and Hypertensive Patients.
The purpose of this study is to determine the effects of candesartan, once daily (QD), on the N-terminal pro-B-type Natriuretic Peptide laboratory marker in subjects with symptomatic heart failure with diastolic dysfunction.
- Trial name
- NCT00775840
- Testing
- Candesartan
- Where
- 37 sites in Germany
- Volunteers
- 22 people
- Sponsor
- Takeda
Tricuspid Regurgitation, Tricuspid Valve Disease
Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation ( VISTA-US)
The purpose of this clinical study is to evaluate the safety and clinical efficacy of the VDyne System in the treatment of symptomatic severe tricuspid regurgitation (TR).
- Conditions
- Tricuspid Regurgitation, Tricuspid Valve Disease, Tricuspid Valvular Disorders
- Trial name
- VISTA-US (NCT05848284)
- Testing
- VDyne Transcatheter Tricuspid Valve Replacement System
- Where
- 11 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- VDyne, Inc.
Coronary Artery Disease
A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES)
PIONEER-II OPC trial is a prospective, multicenter, single-arm registry trial. 1000 subjects from approximately 40 interventional cardiology centers will be enrolled to evaluate the target lesion failure(TLF) as the primary…
- Trial name
- OPC (NCT02698852)
- Testing
- BuMA Supreme
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Sino Medical Sciences Technology Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.